Clik here to view.
OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised...
SAN DIEGO & PENNINGTON, N.J. OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, issued a statement...
View ArticleClik here to view.
Macrogen Research Outcome from ‘GenomeAsia 100K’ Covered in Nature
SEOUL, South Korea The precision medicine and biotechnology company Macrogen (Chairman Jung-Sun Seo, www.macrogen.com) (KOSDAQ: 038290) announced on Dec 5 that the result of its Asian genome...
View ArticleClik here to view.
Macrogen通过GenomeAsia 100K国际联盟获得的研究成果作为《自然》杂志正刊封面论文刊载
韩国首尔 (美国商业资讯)–精密医学生命工程企业Macrogen(会长徐正善 www.macrogen.com)(KOSDAQ: 038290)于5日发布消息称，其通过国际联盟“GenomeAsia 100K倡议（GenomeAsia 100K Initiative）”获得的亚洲人基因组分析研究成果已作为封面论文，刊载于最新一期的《自然（Nature）》杂志上。（论文名称：The...
View ArticleClik here to view.
マクロジェン、ゲノムアジア 100K 国際コンソーシアムの研究成果がネイチャー誌の巻頭論文として掲載
韓国ソウル （ビジネスワイヤ） – 精密医療・バイオテクノロジー企業であるマクロジェン（会長：ソ・ジョンソン, www.macrogen.com)(KOSDAQ: 038290)は国際コンソーシアムである「ゲノムアジア 100K イニシアチブ（GenomeAsia 100K...
View ArticleClik here to view.
LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in...
KENILWORTH, N.J. AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the companies have received marketing authorization from China’s National...
View ArticleClik here to view.
2019年台湾医疗科技展展商简介
台湾台北 (美国商业资讯)–台湾医疗科技展(Healthcare+ Expo Taiwan)将于2019年12月5日至8日在台湾台北市的南港展览馆举行。 美国商业资讯是台湾医疗科技展的官方媒体合作伙伴。以下列出部分参展商资料，展商新闻和公告可在http://www.tradeshownews.com/events/Healthcare-Expo-Taiwan-2019/查询。 参展单位：...
View ArticleClik here to view.
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the...
View ArticleClik here to view.
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual...
View ArticleClik here to view.
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS®...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of...
View ArticleClik here to view.
Maruho和Solasia签署SP-04(PledOx®)代理许可及资本联盟协议
日本东京 (美国商业资讯)–苏爱康制药有限公司（东京证券交易所代码：4597，总部：日本东京，总裁兼首席执行官：荒井好裕，以下简称“苏爱康”）和Maruho有限责任公司（总部：日本大阪，总裁兼首席执行官：Koichi Takagi,...
View ArticleClik here to view.
ソレイジア・ファーマ: 開発品SP-04(効能・効果：がん化学療法に伴う末梢神経障害) 日本における独占的販売ライセンス契約締結および資本提携のお知らせ
東京 （ビジネスワイヤ） — マルホ株式会社（以下「マルホ」）とソレイジア・ファーマ株式会社（以下「ソレイジア」）は、ソレイジアが開発している開発品SP-04...
View ArticleClik here to view.
Solasia Announces License and Capital Alliance for SP-04 (PledOx®) with Maruho
TOKYO Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that it has entered into an exclusive license agreement...
View ArticleClik here to view.
武田薬品がアミロイドーシス患者でニンラーロを検討する第3相TOURMALINE-AL1試験の結果を発表へ
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
武田将呈报评估NINLARO用于淀粉样变患者的3期TOURMALINE-AL1试验结果
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天宣布，TOURMALINE-AL1试验结果将于2019年12月7日周六在佛罗里达州奥兰多召开的美国血液学会(ASH)第61届年会上口述呈报。TOURMALINE-AL1是3期随机临床试验，评估NINLAROTM...
View ArticleClik here to view.
武田在ASH 2019上呈报的研究重点介绍真实世界证据和在研基因治疗药物，展现其促进罕见出血障碍治疗的长期承诺
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502/NYSE:TAK)（“武田”）今天在美国血液学会(ASH)第61届年会上呈报9篇血液学壁报，介绍了该公司通过整合真实世界数据和开发创新腺相关病毒(AAV)基因治疗药物促进罕见出血障碍治疗的承诺。 了解真实世界证据，以促进出血障碍患者为中心的创新...
View ArticleClik here to view.
DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today presented positive detailed data from the global pivotal phase 2...
View ArticleClik here to view.
Fully-human BCMA CAR-T Clinical Results for the Treatment of...
NANJING, China IASO Biotherapeutics (IASO Bio), a clinical-stage biotechnology company advancing the development of innovative therapies for cancer, had the latest clinical data presented on their...
View ArticleClik here to view.
PCI Pharma Services宣布巨额投资，扩建位于英国Tredegar厂区的开发和制造能力
费城 (美国商业资讯)–领先的制药和生物制药全球外包解决方案提供商PCI Pharma Services (PCI)今天宣布，已开始扩建其位于英国威尔士的Tredegar设施，以提升其高效价药物制造和开发能力，包括临床和商业两方面的供货。...
View ArticleClik here to view.
Seattle Genetics和武田在ASH 2019年会上发布 ADCETRIS® (Brentuximab Vedotin)...
华盛顿州博瑟尔和马萨诸塞州剑桥和日本大阪 (美国商业资讯)– Seattle Genetics, Inc. (Nasdaq:SGEN)和武田药品工业株式会社(TSE:4502/NYSE:TAK)今天发布了ECHELON-1和ECHELON-2 ADCETRIS® (brentuximab...
View ArticleClik here to view.
武田薬品、実臨床下でのエビデンスと遺伝子療法治験薬に光を当てる研究の発表をASH 2019で行い、希少出血性疾患の治療を前進させる長期的なコミットメントを示す
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View Article